ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017
Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination.
Registry-linked trialOpen access · bronzeAbstract readClinical Trial, Phase I
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00639639 (Anti-Tumor Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed Glioblastoma Multiforme During Recovery From Therapeutic Temozolomide-induced Lymphopenia), which is not on this map. Cited by 197 papers, 11 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
197citing papers in PubMed, 11 pooled it
19.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Anti-Tumor Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed Glioblastoma Multiforme During Recovery From Therapeutic Temozolomide-induced Lymphopenia
Who cites it
197 citing papers in PubMed, 11 syntheses or guidelines pooled it, 286 citations in OpenAlex.
- Comparative efficacy, immune response, and safety of mRNA versus dendritic cell vaccines in solid tumors: a systematic review and meta-analysis.Journal of translational medicine · 2026Pooled it
- Efficacy and safety of immunotherapy in pediatric malignant brain tumors: a systematic review and exploratory meta-analysis.Frontiers in oncology · 2026Pooled it
- Efficacy of vaccination therapy in newly diagnosed and recurrent glioblastoma patients: a meta-analysis.BMC cancer · 2025Pooled it
- Research progress on the role of dendritic cells in glioma during 1992-2024: a bibliometric analysis.Frontiers in immunology · 2025Pooled it
- Advancements and challenges: immunotherapy therapy in high-grade glioma - a meta-analysis of randomized clinical trials.Journal of neuro-oncology · 2024Pooled it
- Dendritic cell vaccine for glioblastoma: an updated meta-analysis and trial sequential analysis.Journal of neuro-oncology · 2024Pooled it
- Personalised therapeutic approaches to glioblastoma: A systematic review.Frontiers in medicine · 2023Pooled it
- Impact of molecular and clinical variables on survival outcome with immunotherapy for glioblastoma patients: A systematic review and meta-analysis.CNS neuroscience & therapeutics · 2022Pooled it
- Delayed Effect of Dendritic Cells Vaccination on Survival in Glioblastoma: A Systematic Review and Meta-Analysis.Current oncology (Toronto, Ont.) · 2022Pooled it
- Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook.Expert review of clinical pharmacology · 2020Pooled it
- Comparative effect of immunotherapy and standard therapy in patients with high grade glioma: a meta-analysis of published clinical trials.Scientific reports · 2018Pooled it
- Trial
- Autologous CMV-specific T cells are a safe adjuvant immunotherapy for primary glioblastoma multiforme.The Journal of clinical investigation · 2020Trial
- Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Trial
- Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma - a case series.BMC cancer · 2020Trial
- Immunotherapy for Glioma: A compartmental framework for resistance and rational combination design.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Review
- Temozolomide alters the expression pattern of immune mediators in monocyte-derived dendritic cells.Scientific reports · 2026Article
- Review
- The promise of immunotherapy for central nervous system tumours.Nature reviews. Immunology · 2026Review
- mRNA vaccines in cancer immunotherapy: current progress and perspectives in solid tumors and hematologic malignancies.MedScience · 2026Review
137 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 2 institutions in 1 country.
Kristen A BatichDepartment of Neurosurgery, Duke University Medical Center, Durham, North Carolina.
Elizabeth A ReapDepartment of Neurosurgery, Duke University Medical Center, Durham, North Carolina.
Gary E ArcherDepartment of Neurosurgery, Duke University Medical Center, Durham, North Carolina.
Luis Sanchez-PerezDepartment of Neurosurgery, Duke University Medical Center, Durham, North Carolina.
Smita K NairDivision of Surgical Sciences, Department of Surgery, Duke University Medical Center, Durham, North Carolina.
Robert J SchmittlingDepartment of Neurosurgery, Duke University Medical Center, Durham, North Carolina.
Pam NorbergDepartment of Neurosurgery, Duke University Medical Center, Durham, North Carolina.
Weihua XieDepartment of Neurosurgery, Duke University Medical Center, Durham, North Carolina.
James E HerndonDepartment of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina.
Patrick HealyDepartment of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina.
Roger E McLendonDepartment of Pathology, Duke University Medical Center, Durham, North Carolina.
Allan H FriedmanDepartment of Neurosurgery, Duke University Medical Center, Durham, North Carolina.
Henry S FriedmanDepartment of Neurosurgery, Duke University Medical Center, Durham, North Carolina.
Darell BignerDepartment of Neurosurgery, Duke University Medical Center, Durham, North Carolina.
Gordana VlahovicDepartment of Neurosurgery, Duke University Medical Center, Durham, North Carolina.
Duane A MitchellDepartment of Neurosurgery, Duke University Medical Center, Durham, North Carolina. john.sampson@duke.edu duane.mitchell@neurosurgery.ufl.edu.
John H SampsonDepartment of Neurosurgery, Duke University Medical Center, Durham, North Carolina. john.sampson@duke.edu duane.mitchell@neurosurgery.ufl.edu.
Duke University Hospital · USDuke Medical Center · US
Funding
Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI JOHN N. NORTON · 1985 to 2026
$174.8MUsing social networks to map and evaluate team science across CTSA hubsUL1TR001427 · NCATS · UNIVERSITY OF FLORIDA · PI MITCHELL, DUANE A. · 2015 to 2024
$37.2MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007171 · NIGMS · DUKE UNIVERSITY · PI KONTOS, CHRISTOPHER D · 1985 to 2021
$31.2MTargeted Alpha-Particle Radiotheraphy of Brain Tumors with 211At-81C6 AntibodyP50CA190991 · NCI · DUKE UNIVERSITY · PI SAMPSON, JOHN H. · 2014 to 2023
$20.8MVaccine Immunotoxin and Radioimmunotherapy of Primary and Metastatic CNS TumorsP01CA154291 · NCI · DUKE UNIVERSITY · PI BIGNER, DARELL D · 2012 to 2016
$14.5MMedical Scientist Training Program Training GrantT32GM145449 · NIGMS · DUKE UNIVERSITY · PI Christopher D Kontos · 2022 to 2026
$6.6MEfficacy of Dendritic Cell Vaccines Targeting CMV in Glioblastoma (phase 2 DC vaccine)R01CA175517 · NCI · UNIVERSITY OF FLORIDA · PI MITCHELL, DUANE A., SAMPSON, JOHN H. · 2015 to 2020
$3.1MBrain tumors with regulatory T-cells treated with EGFRvIII-specific T-cellsR01CA177476 · NCI · DUKE UNIVERSITY · PI SAMPSON, JOHN H. · 2013 to 2017
$2.3MEGFRvIII-targeted Bispecific T cell Engagers for brain tumorsR01NS085412 · NINDS · DUKE UNIVERSITY · PI SAMPSON, JOHN H. · 2013 to 2017
$2.0MTherapeutic Vaccine Targeting CMV Antigens in GlioblastomaR42CA153845 · NCI · ANNIAS IMMUNOTHERAPEUTICS, INC. · PI SAMPSON, JOHN H. · 2015 to 2017
$2.0MClinical Brain Tumor Development of a Cytomegalovirus-targeted Therapeutic with Vaccine pre-conditioning to Validate Novel Predictors of Vaccine EfficacyR01CA235612 · NCI · DUKE UNIVERSITY · PI SAMPSON, JOHN H. · 2019 to 2022
$2.0MReversal of CMV-specific Immune Deficits in Patients with GlioblastomaR01NS067037 · NINDS · UNIVERSITY OF FLORIDA · PI MITCHELL, DUANE A. · 2009 to 2013
$1.6MNCATS NIH HHS UL1 TR001427NCI NIH HHS F30 CA180411NCI NIH HHS P01 CA154291NCI NIH HHS P30 CA014236NCI NIH HHS P50 CA190991NCI NIH HHS R01 CA134844NCI NIH HHS R01 CA175517NCI NIH HHS R01 CA177476NCI NIH HHS R01 CA235612NCI NIH HHS R42 CA153845NIGMS NIH HHS T32 GM007171NIGMS NIH HHS T32 GM145449NINDS NIH HHS R01 NS067037NINDS NIH HHS R01 NS085412NINDS NIH HHS R01 NS086943NINDS NIH HHS R25 NS065731
Abstract
PubMed holds no abstract for this paper.
Indexed as
Adjuvants, ImmunologicAgedAntineoplastic AgentsBrain NeoplasmsCancer VaccinesCombined Modality TherapyDacarbazineDendritic CellsDisease-Free SurvivalFemaleGlioblastomaGranulocyte-Macrophage Colony-Stimulating FactorHumansKaplan-Meier EstimateMaleMiddle AgedAdjuvants, ImmunologicAntineoplastic AgentsCancer Vaccinescytomegalovirus matrix protein 65kDaDacarbazineGranulocyte-Macrophage Colony-Stimulating FactorPhosphoproteinsTemozolomideViral Matrix Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT00639639ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.